nach oben

Current Diabetes Reports

Erschienen in:

01.02.2010

Cholesterol in β-cell Dysfunction: The Emerging Connection Between HDL Cholesterol and Type 2 Diabetes

verfasst von: Liam R. Brunham, Janine K. Kruit, Michael R. Hayden, C. Bruce Verchere

Erschienen in: Current Diabetes Reports | Ausgabe 1/2010

Einloggen, um Zugang zu erhalten

Abstract

β-cell dysfunction is a critical step in the pathogenesis of type 2 diabetes. The mechanisms responsible for β-cell death and dysfunction remain incompletely understood, but include glucolipotoxicity, the deleterious metabolic milieu created by high plasma concentrations of glucose and lipid species. Recently, an important role has emerged for cholesterol in this process. In this article, we review recent advances in our understanding of the role of ABCA1 and cholesterol metabolism in β-cell function, with particular attention to insights gained from human studies.

Perley MJ, Kipnis DM: Plasma insulin responses to oral and intravenous glucose: studies in normal and diabetic subjects. J Clin Invest 1967, 46:1954–1962.CrossRefPubMed

Kahn SE: The importance of beta-cell failure in the development and progression of type 2 diabetes. J Clin Endocrinol Metab 2001, 86:4047–4058.CrossRefPubMed

Prentki M, Nolan CJ: Islet {beta} cell failure in type 2 diabetes. J Clin Invest 2006, 116:1802–1812.CrossRefPubMed

Unger RH: Lipotoxic diseases. Annu Rev Med 2002, 53:319–336.CrossRefPubMed

Brunham LR, Kruit JK, Verchere CB, et al.: Cholesterol in islet dysfunction and type 2 diabetes. J Clin Invest 2008, 118:403–408.CrossRefPubMed

von Eckardstein A, Schulte H, Assmann G: Risk for diabetes mellitus in middle-aged caucasian male participants of the PROCAM study: implications for the definition of impaired fasting glucose by the American Diabetes Association. J Clin Endocrinol Metab 2000, 85:3101–3108.CrossRef

Timmins JM, Lee JY, Boudyguina E, et al.: Targeted inactivation of hepatic Abca1 causes profound hypoalphalipoproteinemia and kidney hypercatabolism of apoA-I. J Clin Invest 2005, 115:1333–1342.PubMed

Brunham LR, Kruit JK, Iqbal J, et al.: Intestinal ABCA1 directly contributes to HDL biogenesis in vivo. J Clin Invest 2006, 116:1052–1062.CrossRefPubMed

Singaraja RR, Brunham LR, Visscher H, et al.: Efflux and atherosclerosis: the clinical and biochemical impact of variations in the ABCA1 gene. Arterioscler Thromb Vasc Biol 2003, 23:1322–1332.CrossRefPubMed

10.

• Brunham LR, Kruit JK, Pape TD, et al.: Beta-cell ABCA1 influences insulin secretion, glucose homeostasis and response to thiazolidinedione treatment. Nat Med 2007, 13:340–347. This article provides the first evidence that abnormal cholesterol efflux activity in islets leads to cholesterol accumulation and diminished insulin secretion.CrossRefPubMed

11.

Villarreal-Molina MT, Aguilar-Salinas CA, Rodriguez-Cruz M, et al.: The ABCA1 R230C variant affects HDL-cholesterol levels and body mass index in the Mexican population: association with obesity and obesity-related comorbidities. Diabetes 2007, 56:1881–1887.CrossRefPubMed

12.

Villarreal-Molina MT, Flores-Dorantes MT, Arellano-Campos O, et al.: Association of the ATP-binding cassette transporter A1 R230C variant with early-onset type 2 diabetes in the Mexican population. Diabetes 2008, 57:509–513.CrossRefPubMed

13.

Wang J, Burnett JR, Near S, et al.: Common and rare ABCA1 variants affecting plasma HDL cholesterol. Arterioscler Thromb Vasc Biol 2000, 20:1983–1989.PubMed

14.

Koseki M, Matsuyama A, Nakatani K, et al.: Impaired insulin secretion in four Tangier disease patients with ABCA1 mutations. J Atheroscler Thromb 2009, 16:292–296.PubMed

15.

Schaefer EJ, Brousseau ME, Diffenderfer MR, et al.: Cholesterol and apolipoprotein B metabolism in Tangier disease. Atherosclerosis 2001, 159:231–236.CrossRefPubMed

16.

Xia F, Xie L, Mihic A, et al.: Inhibition of cholesterol biosynthesis impairs insulin secretion and voltage-gated calcium channel function in pancreatic {beta}-cells. Endocrinology 2008, 149:5136–5145.CrossRefPubMed

17.

Xia F, Gao X, Kwan E, et al.: Disruption of pancreatic beta-cell lipid rafts modifies Kv2.1 channel gating and insulin exocytosis. J Biol Chem 2004, 279:24685–24691.CrossRefPubMed

18.

Vikman J, Jimenez-Feltstrom J, Nyman P, et al.: Insulin secretion is highly sensitive to desorption of plasma membrane cholesterol. FASEB J 2009, 23:58–67.CrossRefPubMed

19.

Kennedy MA, Barrera GC, Nakamura K, et al.: ABCG1 has a critical role in mediating cholesterol efflux to HDL and preventing cellular lipid accumulation. Cell Metab 2005, 1:121–131.CrossRefPubMed

20.

Yvan-Charvet L, Ranalletta M, Wang N, et al.: Combined deficiency of ABCA1 and ABCG1 promotes foam cell accumulation and accelerates atherosclerosis in mice. J Clin Invest 2007, 117:3900–3908.PubMed

21.

Out R, Jessup W, Le Goff W, et al.: Coexistence of foam cells and hypocholesterolemia in mice lacking the ABC transporters A1 and G1. Circ Res 2008, 102:113–120.CrossRefPubMed

22.

Goldstein JL, Bose-Boyd RA, Brown MS: Protein sensors for membrane sterols. Cell 2006, 124:35–46.CrossRefPubMed

23.

Horton JD, Shimomura I, Brown MS, et al.: Activation of cholesterol synthesis in preference to fatty acid synthesis in liver and adipose tissue of transgenic mice overproducing sterol regulatory element-binding protein-2. J Clin Invest 1998, 101:2331–2339.CrossRefPubMed

24.

• Ishikawa M, Iwasaki Y, Yatoh S, et al.: Cholesterol accumulation and diabetes in pancreatic {beta}-cell-specific SREBP-2 transgenic mice: a new model for lipotoxicity. J Lipid Res 2008, 49:2524–2534. This article reports the results of mice that overexpress SREBP-2 specifically in β cells, leading to cholesterol accumulation and islet dysfunction.CrossRefPubMed

25.

Zeng L, Liao H, Liu Y, Lee TS, et al.: Sterol-responsive element-binding protein (SREBP) 2 down-regulates ATP-binding cassette transporter A1 in vascular endothelial cells. J Biol Chem 2004, 279:48801–48807.CrossRefPubMed

26.

Roehrich ME, Mooser V, Lenain V, et al.: Insulin-secreting beta-cell dysfunction induced by human lipoproteins. J Biol Chem 2003, 278:18368–18375.CrossRefPubMed

27.

Cnop M, Hannaert JC, Grupping AY, et al.: Low density lipoprotein can cause death of islet beta-cells by its cellular uptake and oxidative modification. Endocrinology 2002, 143:3449–3453.CrossRefPubMed

28.

Grupping AY, Cnop M, Van Schravendijk CFH, et al.: Low density lipoprotein binding and uptake by human and rat islet beta cells. Endocrinology 1997, 138:4064–4068.CrossRefPubMed

29.

Rutti S, Ehses JA, Sibler RA, et al.: Low- and high-density lipoproteins modulate function, apoptosis, and proliferation of primary human and murine pancreatic {beta}-cells. Endocrinology 2009, 150:4521–4530.CrossRefPubMed

30.

•• Drew BG, Duffy SJ, Formosa MF, et al.: High-density lipoprotein modulates glucose metabolism in patients with type 2 diabetes mellitus. Circulation 2009, 119:2103–2111. This article provides the first evidence that HDL-based therapies may have beneficial effects on islet function in humans.CrossRefPubMed

31.

Nissen SE, Tsunoda T, Tuzcu EM, et al.: Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA 2003, 290:2292–2300.CrossRefPubMed

32.

Badimon JJ, Badimon L, Fuster V: Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit. J Clin Invest 1990, 85:1234–1241.CrossRefPubMed

33.

Miyazaki A, Sakuma S, Morikawa W, et al.: Intravenous injection of rabbit apolipoprotein A-I inhibits the progression of atherosclerosis in cholesterol-fed rabbits. Arterioscler Thromb Vasc Biol 1995, 15:1882–1888.PubMed

34.

Shepherd J, Cobbe SM, Ford I, et al.: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995, 333:1301–1308.CrossRefPubMed

35.

Freeman DJ, Norrie J, Sattar N, et al.: Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation 2001, 103:357–362.PubMed

36.

Ridker PM, Danielson E, Fonseca FA, et al.: Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008, 359:2195–2207.CrossRefPubMed

37.

Rajpathak SN, Kumbhani DJ, Crandall J, et al.: Statin therapy and risk of developing type 2 diabetes: a meta-analysis. Diabetes Care 2009, 32:1924–1929.CrossRefPubMed

38.

Sugiyama S, Fukushima H, Kugiyama K, et al.: Pravastatin improved glucose metabolism associated with increasing plasma adiponectin in patients with impaired glucose tolerance and coronary artery disease. Atherosclerosis 2007, 194:e43–e51.CrossRefPubMed

39.

Tsutamoto T, Yamaji M, Kawahara C, et al.: Effect of simvastatin vs. rosuvastatin on adiponectin and haemoglobin A1c levels in patients with non-ischaemic chronic heart failure. Eur J Heart Fail 2009, 11:1195–1201.CrossRefPubMed

40.

Li S, Shin HJ, Ding EL, et al.: Adiponectin levels and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA 2009, 302:179–188.CrossRefPubMed

41.

Chinetti G, Lestavel S, Bocher V, et al.: PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nat Med 2001, 7:53–58.CrossRefPubMed

42.

Wang J, Bao YQ, Hu C, et al.: Effects of ABCA1 variants on rosiglitazone monotherapy in newly diagnosed type 2 diabetes patients. Acta Pharmacol Sin 2008, 29:252–258.CrossRefPubMed

43.

Park SE, Kang ES, Kim DH, et al.: Effect of ABCA1 variant on atherogenic dyslipidaemia in patients with type 2 diabetes treated with rosiglitazone. Diabet Med 2009, 26:577–581.CrossRefPubMed

Titel: Cholesterol in β-cell Dysfunction: The Emerging Connection Between HDL Cholesterol and Type 2 Diabetes
verfasst von: Liam R. Brunham
Janine K. Kruit
Michael R. Hayden
C. Bruce Verchere
Publikationsdatum: 01.02.2010
Verlag: Current Science Inc.
Erschienen in: Current Diabetes Reports / Ausgabe 1/2010
Print ISSN: 1534-4827
Elektronische ISSN: 1539-0829
DOI: https://doi.org/10.1007/s11892-009-0090-x

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

25.04.2024 | Hypotonie | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Cholesterol in β-cell Dysfunction: The Emerging Connection Between HDL Cholesterol and Type 2 Diabetes

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2010

Does Choice of Antidiabetes Therapy Influence Macrovascular Outcomes?

Postprandial Lipoproteins and Cardiovascular Disease Risk in Diabetes Mellitus

Multifactorial Intervention to Reduce Cardiovascular Events in Type 2 Diabetes

Pleiotropic Effects of Inhibitors of the RAAS in the Diabetic Population: Above and Beyond Blood Pressure Lowering

The Role of Revascularization Versus Medical Therapy in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease

The Emerging Role of Biomarkers in Diabetic and Hypertensive Chronic Kidney Disease

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin